scholarly journals O14‐3: Diagnostic and dynamic circulating methylated DNA markers for non‐small cell lung cancer

Respirology ◽  
2021 ◽  
Vol 26 (S3) ◽  
pp. 39-39
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Dna Markers ◽  
Small Cell ◽  
Small Cell Lung ◽  
Methylated Dna

scholarly journals A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA

2017 ◽  
Vol 23 (22) ◽  
pp. 7141-7152 ◽  
Author(s):  
Akira Ooki ◽  
Zahra Maleki ◽  
Jun-Chieh J. Tsay ◽  
Chandra Goparaju ◽  
Mariana Brait ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Dna Markers ◽  
Small Cell ◽  
Small Cell Lung ◽  
Methylated Dna ◽  
Serum Dna

Evaluation of platinum-based chemotherapy, glutathione metabolic genes, and survival in advanced non small cell lung cancer: A NCCTG 97–24–51 based study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 13013-13013 ◽  
Author(s):  
P. Yang ◽  
S. J. Mandrekar ◽  
S. L. Hillman ◽  
K. L. Allen ◽  
Z. Sun ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Metabolic Pathway ◽  
Dna Markers ◽  
Small Cell ◽  
Advanced Lung Cancer ◽  
Small Cell Lung ◽  
Platinum Based Chemotherapy ◽  
Significant Difference

13013 Background: The glutathione metabolic pathway is directly involved in the inactivation of platinum compounds. Our earlier work indicated that genotypes corresponding to varied glutathione-related enzyme activities may predict survival in patients with advanced lung cancer. Herein, we evaluated the role of glutathione-related genotypes on clinical outcomes in stage IIIB/IV non-small cell lung cancer patients who were stable or responding from one prior platinum-based chemotherapy. Methods: DNA samples from patients who had tumor regression or stable disease after treatment with one platinum based chemotherapy regimen were analyzed using 6 polymorphic DNA markers that encode 5 important enzymes in the glutathione metabolic pathway. The contrasting genotypes used in the analysis were GCLC (homozygous repeat 77 vs. heterozygous 7*), GPX1 (CC vs. other), GSTP1-I105V (AA vs. other), GSTP1-A114V (CC vs. other), GSTM1 (null vs. present), and GSTT1 (null vs. present). Multivariable Cox proportional hazards models adjusted for age, gender, treatment arm, ECOG performance status, stage, and prior tumor response, were used to evaluate the prognostic significance of the genotypes at each locus. Results: Data from 112 patients with a median follow-up of 10.6 (range: 0.4–56.3) months was used. No significant difference in time to disease progression was observed for any of the genotypes. Among the 6 genomic DNA markers, the GCLC genotype was an important prognostic factor for overall survival after adjusting for other factors. In particular, patients carrying a 77 repeat genotype (homozygous) had a significantly worse survival (Hazard ratio = 1.67, 95% CI: 1.05–2.63). Conclusions: Genotypes of glutathione-related enzymes, especially GCLC, may be used as host factors in predicting patients’ prognosis after platinum-based chemotherapy. Further investigation to define and measure the effects of these genes in chemotherapeutic regimens is needed. (This work was partly supported by NIH research grants CA77118, CA80127, and CA84354.) No significant financial relationships to disclose.

scholarly journals The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer

2021 ◽  
Vol 10 (2) ◽  
pp. 855-865
Author(s):  
Sara Witting Christensen Wen ◽  
Rikke Fredslund Andersen ◽  
Torben Frøstrup Hansen ◽  
Christa Haugaard Nyhus ◽  
Henrik Hager ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Prognostic Impact ◽  
Small Cell Lung ◽  
Methylated Dna
Sign in / Sign up

Export Citation Format

Share Document